Table 1.
1. Modulation of Calcium Currents | |||||
1.1 Through Direct Involvement in Calcium Influx/Efflux | |||||
1.1.1 SOCE | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
ORAI1 | Ca2+ | Neutrophils, Lymphocytes |
Neutrophils: proliferation, degranulation, cytokines production, cell polarization, migrational guidance with LFA1. Lymphocytes: B, T and NK cell proliferation, cytokine production and/or cytotoxicity in vitro; immunity to infection, T cell-mediated autoimmunity and inflammation, and allogeneic T cell responses in vivo; Treg cell development |
CRAC channelopathywith immunodeficiency, autoimmunity, lymphoproliferation, muscular hypotonia and ectodermal dysplasia caused by mutations in STIM1 and ORAI1 | [10,27,60,61] |
ORAI2/3 | Ca2+ | Neutrophils, Lymphocytes | Cell proliferation, Cytokines production | ND | |
STIM1 | NA | Neutrophils, Lymphocytes, DC, mast cells |
Neutrophils: phagocytosis and ROS production Lymphocytes: cytokine production in T and B cells, Treg functionality Mast cells: FcεR-triggered SOCE |
ND | [13,14,27,62,63,64] |
STIM2 | NA | Mice deficient of STIM1/2 develop a lymphoproliferative disorder because of dysfunction of Treg cells. | |||
IP3Rs | Ca2+ | All cells | Physiological development of B and T cells | ND | [16,17,18,19] |
TRPC1 | Ca2+, Na+ | Endothelium | Enhanced vascular permeability after TNF/thrombin stimulation | ND | [65,66,67] |
TRPC6 | Ca2+, Na+ | Platelets | Dense granules secretion after thrombin stimulation | ND | [68] |
1.1.2 ROCE | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPM2 | Ca2+, Na+ | Neutrophils, lymphocytes, macrophages and DC |
Neutrophils: increased activation and endothelial adhesion Lymphocytes: T cell proliferation and cytokine secretion Macrophages and dendritic cells: regulation of ROS formation |
Mice lacking TRPM2 have milder ischaemia-reperfusion injury after myocardial infarction and attenuated experimental brain inflammation | [54,69,70,71,72,73,74,75] |
TRPC3 | Ca2+, Na+ | Lymphocytes, macrophages |
Lymphocytes: T cell activation downstream the TCR Macrophages: enhanced pro-inflammatory activation |
Mice: accelerated atherosclerosis | [76,77,78] |
TRPC6 | Ca2+, Na+ | Lymphocytes, neutrophils, endothelium, platelets |
Lymphocytes: T cell activation Neutrophils: chemotaxis, Endothelium: enhanced endothelial permeability and activation Platelets: TXA2-dependent expression of glycoproteins IIb-IIIa and P-selectin, release of platelet dense granules |
Mice: TRPC6 ko associates with milder airway hypersensitivity in asthma models Humans: single study suggesting an association between a TRPC6 polymorphism and neuropsychiatric SLE |
[79,80,81,82,83,84,85] |
TRPV4 | Ca2+, Na+ | Macrophages | Cell activation after lung barotrauma. | Mice: exacerbated lung inflammation in acute lung injury and increased inflammatory hyperalgesia | [30] |
P2X1R, P2X4R | Ca2+, Na+ | Lymphocytes, neutrophils, eosinophils, monocytes/macrophages, mast cells, and DC |
Lymphocytes: T cell proliferation; cytokine production; thymocyte apoptosis Macrophages: PGE2 release, inflammasome activation |
ND | [86,87] |
P2X7R | Ca2+, Na+, other cations |
Lymphocytes: T cell survival and cytokine production (downstream the TCR); T cell differentiation into Th17 vs. Treg Macrophages: activation of the NLRP3 inflammasome Mast cells, eosinophils, DC: inflammatory activation |
Mice lacking P2X7R have attenuated allergic airway response, graft vs. host disease, allograft rejection | [88,89,90] | |
1.1.3 VOCE | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
Cav1.1-4 | Ca2+ | Lymphocytes | T cell survival, differentiation and progression to effector function | ND | [31,32] |
1.1.4 Direct calcium entry following upregulation | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPC3 | Ca2+, Na+ | Macrophages/microglia | Regulation of cellular activation | Mice: reduced brain inflammation and post-ischaemic myocardial damage | [28,91,92] |
TRPC5 | Ca2+, Na+ | Lymphocytes | Inhibition of Teff activation by Treg | Mice: protection from experimental arthritis | [93,94] |
TRPV1 | Ca2+, Na+ | T lymphocytes | Cell activation (by associating to TCR) | ND | [95] |
TRPV2 | Ca2+, Na+ | Macrophages | Phagocytosis, chemotaxis, following FCγR activation | Mice: TRPV2 deletion prompts accelerated mortality in bacterial infections Humans: cystic Fibrosis macrophages exhibit a defect in TRPV2-mediated calcium influx |
[51,96] |
TRPV5,6 | Ca2+, Na+ | Lymphocytes | Cell activation and proliferation (the channels are constitutively active and regulated by endocytosis or at gene expression level). | ND | [97] |
1.2 Through intracellular second messengers | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPM7 | Mg2+, Ca2+ | Lymphocytes, macrophages, mast cells | Lymphocytes: activation downstream BCR and TCR; thymocyte development; production of thymocyte growth factor Macrophages: survival and M2 polarisation Mast cells: survival and activation |
ND | [98,99,100,101,102,103] |
MAGT1 | Mg2+ | Lymphocytes | CD4+ T cell development and activation; immunity to EBV | XMEN syndrome (X-linked mutations in MAGT1) | [104] |
ZIP6 | Zn2+ | T cells, DC |
T cells: sustained calcium currents enhancing TCR-related pathways and promoting T cell activation DC: inhibition of maturation for antigen presentation |
Genetically determined zinc deficit (mutated ZIP4 in the intestinal mucosa) causes acrodermatitis enteropathica with immunodeficiency | [26] |
ZIP8 | T cells | Sustained calcium currents enhancing TCR-related pathways and promoting T cell activation | |||
1.3 Through alterations of cell polarisation | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
NCX1 | Ca2+, Na+ | NeutrophilsMacrophages | Neutrophils: recovery from activation Macrophages: activation, cytokine (TNF) secretion |
A single association study suggests potential links among NCX polymorphisms and SLE phenotypes (including severe nephritis) | [11,43,44] |
NKCC2 | Na+, K+, 2Cl− | Lymphocytes | Adaptation to extracellular hypertonicity, which eventually leads to the activation of the p38/MAPK → NFAT5 → SGK pathway, which favours Th17 differentiation | ND | [37] |
ENaC | Na+ | ||||
NHE1 | Na+, H+ | ||||
TRPM4 | Na+, Ca2+ | Lymphocytes, macrophages and DC, mast cells |
Lymphocytes: T helper motility and cytokine production (IL2, IL4, and IFNγ). Macrophages: phagocytosis and cytokine release DC: motility Mast cells: regulation of cell activation |
Mice: lack of TRPM4 associates with reduced survival in sepsis and more intense anaphylaxis | [105,106,107,108] |
GABAA-R | Cl− | Lymphocytes, macrophages and DC, neutrophils | Inhibition of cell activation | In preclinical models GABAergic drugs, protects against type 1 diabetes (T1D), experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), contact dermatitis and allergic asthma. Treatment with gabapentin and pregabalin improved psoriasis (case report). | [49] |
CFTR | Cl− | Lymphocytes, macrophages |
Lymphocytes: modulation of cytokine secretory profile (IL5, IL10) in T cells Macrophages: cytokine release, phagocytosis |
Cystic fibrosis | [51,109] |
Kv1.3 | K+ | Lymphocytes | Enhanced activation of the NLRP3 inflammasome and of IL1β production. Enhanced cell survival and prolonged activation. | A single phase Ib study on dalazatide (a specific Kv1.3 inhibitor) shows promise. Applications in SLE have been proposed. | [110,111,112] |
KCa3.1 | K+ | Lymphocytes, macrophages, endothelium |
Lymphocytes: sustained TCR-induced calcium currents to support long-lasting effector functions. Macrophages: activation, chemotaxis, infiltration of atherosclerotic plaques Endothelium: proliferation |
Encouraging evidence of efficacy of KCa3.1blockers in several models of inflammatory vasculopathy and autoimmunity. | [47,113,114,115,116] |
Nav1.5 (SCN5A) | Na+ | T cells | Positive selection of thymocytes | ND | [46] |
P2X7R | Ca2+, Na+ and other cations | Macrophages | Cell death for prolonged depolarisation in case of sustained receptor ligation. | ND | [117] |
1.4 Through alterations in the geographical distribution of intracellular calcium | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPC1 | Ca2+, Na+ | Neutrophils | Cell polarisation for chemotaxis | ND | [65,66,67] |
2. Modulation of intracellular pH and production of reactive oxygen species | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPM2 | Ca2+, Na+ | Macrophages and DC | Macrophages and DC: regulation of ROS formation, phagocytosis and bacterial killing | ND | [71,75] |
Hv1/VSOP | H+ | lymphocytes, granulocytes, macrophages and DC | All cells: phagocytosis and ROS production B cells: BCR signalling |
Mice: loss of the receptor prompts impaired killing of phagocytosed bacteria, ROS production and migration by leukocytes and impaired antibody responses. | [15,53] |
NCX | Ca2+, Na+ | DC | Activation of NADPH oxidase and polarisation towards pro-inflammatory DC. | [42] | |
ENac | Na+ | ||||
NHE | Na+, H+ | ||||
3. Modulation of endosomal pH | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPC6 | Ca2+, Na+ | Macrophages | Phagocytosis and bacterial killing | ND | [8] |
TRPM2 | Ca2+, Na+ | Macrophages and DC | Phagocytosis and bacterial killing | ND | [71,75] |
Proton ATPases | H+ | Macrophages | Phagocytosis and bacterial killing | ND | [118] |
Nav1.5 (SCN5A) | Na+ | Macrophages | endosomal acidification and phagocytosis. Possible polarisation towards an antinflammatory phenotype | Mice: enhanced recovery from EAE. | [45,119] |
CLIC 1 | Cl− | Macrophages and DC | Phagocytosis, antigen processing and presentation. | ND | [9,120] |
4. Modulation of other intracellular signalling pathways | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
TRPC1 | Ca2+, Na+ | Macrophages, Mast cells |
Macrophages: inhibition of IL1β through other ion channels and transporters Mast-cells: inhibition of calcium-dependent release of TNF in the late phase of cell activation |
Mice: delayed recovery from anaphylaxis | [77,121] |
5. Other effects | |||||
Channel | Permeability | Expression (immune cells) | Biological effects | Clinical correlates | Ref. |
SLC5A11 | Na+, glucose | Leukocytes (low) | Leukocytes: control of cell osmolarity under hypernatriemic environment, energy uptake, TNF-dependent apoptosis | Polymorphisms associated with susceptibility to SLE | [55,122] |
CLIC 1 | Cl− | Macrophages | Modulation of cytokine gene expression and processing (conflicting results) | ND | [9,58,59] |
CLIC 4 | Cl− |
Abbreviations. Cav: voltage-gated calcium channels; CFTR: cystic fibrosis transmembrane conductance regulator; CLIC: chloride intracellular channels; DC: dendritic cells; EAE: experimental allergic encephalomyelitis; ENaC: epithelial sodium channel; GABAA-R: gamma-aminobutyric acid receptor type A; NADPH: nicotinamide adenine dinucleotide phosphate; NCX1: sodium-calcium exchanger 1; ND: not determined; NHE1: sodium-hydrogen exchanger 1; NKCC2: sodium-potassium-2 chloride exchanger; PGE2: prostaglandin E2; ROCE: receptor-operated calcium entry; SLC5A11: sodium glucose cotransporter; SOCE: store-operated calcium entry; STIM: stromal interaction molecule; TCR, T cell receptor; TRP: transient receptor potential channel; TXA2: thromboxane A2; VOCE: voltage-operated calcium entry; VSOP: voltage-sensing domain only protein; XMEN, X-linked immunodeficiency with Mg2+ defect and EBV infection and neoplasia; ZIP: zinc-regulated transporter (ZRT)/iron regulated transporter(IRT)-like protein.